Gimv successfully exits Prosensa
Today, Gimv sold its remaining stake in the Dutch listed biotech company Prosensa (ticker: RNA:US). Gimv supported the development of the company through subsequent financing rounds since its initial investment in December 2008.
This exit has resulted in an uplift on the last published equity value as per 30 September 2014 of EUR 8.5 million (EUR 0.33 per share). In total, Gimv realizes a money multiple of 4.6x on its historical investment cost, resulting in a return significantly higher than its long term average return.